Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP250953.RABGvVnzHXHoEh5-v2biSwVV4_Bpwln6ZNwZTlBd_eyv8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP250953.RABGvVnzHXHoEh5-v2biSwVV4_Bpwln6ZNwZTlBd_eyv8130_assertion type Assertion NP250953.RABGvVnzHXHoEh5-v2biSwVV4_Bpwln6ZNwZTlBd_eyv8130_head.
- NP250953.RABGvVnzHXHoEh5-v2biSwVV4_Bpwln6ZNwZTlBd_eyv8130_assertion description "[Here, we assessed the effect of a novel and selective EP4 antagonist MF498 [N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide] on inflammation in adjuvant-induced arthritis (AIA), a rat model for rheumatoid arthritis (RA), and joint pain in a guinea pig model of iodoacetate-induced osteoarthritis (OA).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP250953.RABGvVnzHXHoEh5-v2biSwVV4_Bpwln6ZNwZTlBd_eyv8130_provenance.
- NP250953.RABGvVnzHXHoEh5-v2biSwVV4_Bpwln6ZNwZTlBd_eyv8130_assertion evidence source_evidence_literature NP250953.RABGvVnzHXHoEh5-v2biSwVV4_Bpwln6ZNwZTlBd_eyv8130_provenance.
- NP250953.RABGvVnzHXHoEh5-v2biSwVV4_Bpwln6ZNwZTlBd_eyv8130_assertion SIO_000772 18287210 NP250953.RABGvVnzHXHoEh5-v2biSwVV4_Bpwln6ZNwZTlBd_eyv8130_provenance.
- NP250953.RABGvVnzHXHoEh5-v2biSwVV4_Bpwln6ZNwZTlBd_eyv8130_assertion wasDerivedFrom befree-20140225 NP250953.RABGvVnzHXHoEh5-v2biSwVV4_Bpwln6ZNwZTlBd_eyv8130_provenance.
- NP250953.RABGvVnzHXHoEh5-v2biSwVV4_Bpwln6ZNwZTlBd_eyv8130_assertion wasGeneratedBy ECO_0000203 NP250953.RABGvVnzHXHoEh5-v2biSwVV4_Bpwln6ZNwZTlBd_eyv8130_provenance.